Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ted collaboration with GSK. As part of Regulus' strategic alliance with GSK, Regulus received a $15 million upfront fee, which it began amortizing into revenue in the second quarter of 2008 and will continue to amortize over its six-year period of performance under the agreement.

Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $1.8 million and $3.0 million for the three and six months ended June 30, 2008. With the recently announced strategic alliance with GSK, it is anticipated that Regulus' expenses will increase as Regulus continues to advance its research and development activities. The GSK alliance enhances Regulus' ability to expand operations and advance its programs. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.2 million and $2.2 million for the three and six months ended June 30, 2008. Regulus' non-cash compensation expense related to stock options was $681,000 and $1.1 million for the three and six months ended June 30, 2008. Because Regulus was formed in the third quarter of 2007, it did not have operating results in the first half of 2007.

Quarterly Highlights

"Since the completion of our Genzyme collaboration, we've made great progress with mipomersen by initiating the first of four studies scheduled to begin by year end and receiving a patent allowance that gives the Isis-Genzyme Apolipoprotein B franchise broad protection of mipomersen and other antisense apoB compounds. In addition to the successes of our partnered drugs and satellite companies in the first half of the year, we continue to maximize the economic potential of our business model and our technology, while enabling the advancement of a broad portfolio of both partnered and internally developed drugs," concluded Ms. Parshall.

Cardiovascular Program

-- Completed licensing transaction for mipomersen

-- Finalized and announ
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Norway, April 23 HUNT Biosciences, the,commercial arm ... announced the,appointment of former GE Healthcare director Per ... and healthcare companies with biomarker,discovery and validation services. ... for the past 25 years has gathered blood ...
... Akaza Research will be conducting a presentation and exhibiting OpenClinica at ... Colorado Convention Center in Denver, CO. , ... Denver, ... Exhibition of the Association of Clinical Research Professionals (ACRP) will include ...
... Inc. (Nasdaq: TRBN ) announced today ... therapeutic technology at the 100th Annual Meeting of ... Denver. The data presented demonstrated the selectivity and ... its differentiation from monospecific approaches, and its potential ...
Cached Biology Technology:Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences 2Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 4
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... uncovered the complex structure of a protein that serves ... details about the molecule necessary for developing useful new ... published online today in the journal Science details this ... basic and critical processes. , "Understanding this ...
... of heart patients to have high-tech devices implanted in their ... are designed to shock damaged hearts back into rhythm and ... each year. , But a new study finds that while ... large number won't -- and a simple heart-rhythm test can ...
... can grow new extensions when the amount of three particular ... , The research examined three related receptor proteins, called GPR3, ... rats. , When researchers increased the amount of ... to three times longer than those on nerve cells with ...
Cached Biology News:Columbia scientists determine 3-dimensional structure of cell's 'fuel gauge' 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 33 proteins may play important role in nerve-cell repair 2
... is an optical unit that can be ... Dyad Disciple gradient-capable thermal cycler (purchased separately). ... shuttle that contains four LEDs for fluorescence ... 620-650 nm) and two filtered photodiodes for ...
... Laser Capture Microdissection (LCM) is the ... worldwide. Veritas Microdissection is the only instrument ... providing unmatched flexibility., UV Laser ... ,Ideal for non-soft tissues and capturing large ...
... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: